Swiss Prime Site AG (0QOG)
London Exchange · UK · prices in GBP · close of 21 Oct 2026
Key indicators
| Last close | GBP 124.90 |
|---|---|
| 52-week range | 112.59 – 147.48 |
| Return, 1 month / 3 months | −1.2% / −5.3% |
| Return, 1 year / 3 years | +11.0% / +50.8% |
| Trend | Below its 200-day average |
| RSI (14) | 60 |
| Volatility (1 year) | 14.7% |
| Worst drawdown (1 year) | -18.5% |
| Average daily value traded | 2.28M GBP |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Swiss Prime Site is a real estate company based in Switzerland that owns, develops and manages commercial property, with a focus on office buildings, retail space and mixed-use sites in Swiss cities. Its customers are mainly businesses and retailers that lease space in its properties, and it also provides real estate services and asset management. The company runs a department store business alongside its property activities, giving it a mix of rental income and retail operations.
On this site Swiss Prime Site AG appears as a stock on the London Exchange (UK), code 0QOG, with prices in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Swiss Prime Site AG (0QOG) trades on the London Exchange in UK. It last closed at GBP 124.90 on 21 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 1,843 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.0% and over the last three months it fell 5.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 40 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.6% | ||
| From 52-week high | -14.7% | ||
| Momentum | 43 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -5.3% | ||
| 6-month return | -7.9% | ||
| 12-month return, skipping the last month | 12.3% | ||
| Stability (higher is calmer) | 85 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 14.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.5% | ||
| Liquidity | 61 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.28M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | 23 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.7% |
|---|---|
| 1 month | −1.2% |
| 3 months | −5.3% |
| 6 months | −7.9% |
| 1 year | +11.0% |
| 3 years | +50.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 124.53 / 130.90 |
|---|---|
| Golden / death cross (60 days) | Death, 36 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.33 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Mar 2026 | GBX 0.0175 |
| 21 Mar 2025 | GBX 0.0173 |
| 26 Mar 2024 | GBX 0.0170 |
| 28 Mar 2023 | GBX 0.0170 |
| 9 Jun 2022 | GBX 0.0168 |
| 28 Mar 2022 | GBX 0.0168 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.